Loss of haspin suppresses cancer cell proliferation by interfering with cell cycle progression at multiple stages.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
10 2021
Historique:
revised: 18 08 2021
received: 16 01 2021
accepted: 31 08 2021
entrez: 22 9 2021
pubmed: 23 9 2021
medline: 28 10 2021
Statut: ppublish

Résumé

Our recent studies have shown that haspin, a protein kinase imperative for mitosis, is engaged in the interphase progression of HeLa and U2OS cancer cells. In this investigation, we employed the Fucci reporter system and time-lapse imaging to examine the impact of haspin gene silencing on cell cycle progressions at a single-cell level. We found that the loss of haspin induced multiple cell cycle defects. Specifically, the S/G2 duration was greatly prolonged by haspin gene depletion or inhibition in synchronous HeLa cells. Haspin gene depletion in asynchronous HeLa and U2OS cells led to a similarly protracted S/G2 phase, followed by mitotic cell death or postmitotic G1 arrest. In addition, haspin deficiency resulted in robust induction of the p21

Identifiants

pubmed: 34551143
doi: 10.1096/fj.202100099R
doi:

Substances chimiques

Fluorescent Dyes 0
Intracellular Signaling Peptides and Proteins 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0
5-iodotubercidin 24386-93-4
HASPIN protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Tubercidin M351LCX45Y

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e21923

Informations de copyright

© 2021 Federation of American Societies for Experimental Biology.

Références

Higgins JM. Haspin: a newly discovered regulator of mitotic chromosome behavior. Chromosoma. 2010;119:137-147.
Dai J, Sultan S, Taylor SS, Higgins JM. The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev. 2005;19:472-488.
Dai J, Sullivan BA, Higgins JM. Regulation of mitotic chromosome cohesion by Haspin and Aurora B. Dev Cell. 2006;11:741-750.
Dai J, Kateneva AV, Higgins JM. Studies of haspin-depleted cells reveal that spindle-pole integrity in mitosis requires chromosome cohesion. J Cell Sci. 2009;122:4168-4176.
Kurihara D, Matsunaga S, Omura T, Higashiyama T, Fukui K. Identification and characterization of plant Haspin kinase as a histone H3 threonine kinase. BMC Plant Biol. 2011;11:73.
Wang Q, Wei H, Du J, et al. H3 Thr3 phosphorylation is crucial for meiotic resumption and anaphase onset in oocyte meiosis. Cell Cycle. 2016;15:213-224.
Xie J, Wooten M, Tran V, et al. Histone H3 threonine phosphorylation regulates asymmetric histone inheritance in the drosophila male germline. Cell. 2015;163:920-933.
Nguyen AL, Gentilello AS, Balboula AZ, Shrivastava V, Ohring J, Schindler K. Phosphorylation of threonine 3 on histone H3 by Haspin kinase is required for meiosis I in mouse oocytes. J Cell Sci. 2014;127:5066-5078.
Panigada D, Grianti P, Nespoli A, et al. Yeast Haspin kinase regulates polarity cues necessary for mitotic spindle positioning and is required to tolerate mitotic arrest. Dev Cell. 2013;26:483-495.
Wang F, Dai J, Daum JR, et al. Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science. 2010;330:231-235.
Hadders MA, Hindriksen S, Truong MA, et al. Untangling the contribution of Haspin and Bub1 to Aurora B function during mitosis. J Cell Biol. 2020;219:e201907087.
De Antoni A, Maffini S, Knapp S, Musacchio A, Santaguida S. A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B. J Cell Biol. 2012;199:269-284.
Wang F, Ulyanova NP, Daum JR, et al. Haspin inhibitors reveal centromeric functions of Aurora B in chromosome segregation. J Cell Biol. 2012;199:251-268.
Yi Q, Chen Q, Liang C, et al. HP1 links centromeric heterochromatin to centromere cohesion in mammals. EMBO Rep. 2018;19:e45484.
Liang C, Chen Q, Yi Q, et al. A kinase-dependent role for Haspin in antagonizing Wapl and protecting mitotic centromere cohesion. EMBO Rep. 2018;19:43-56.
Goto Y, Yamagishi Y, Shintomi-Kawamura M, Abe M, Tanno Y, Watanabe Y. Pds5 regulates sister-chromatid cohesion and chromosome Bi-orientation through a conserved protein interaction module. Curr Biol. 2017;27:1005-1012.
Zhou L, Liang C, Chen Q, et al. The N-Terminal non-kinase-domain-mediated binding of Haspin to Pds5B protects centromeric cohesion in mitosis. Curr Biol. 2017;27:992-1004.
Hindriksen S, Bramer AJ, Truong MA, et al. Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells. PLoS One. 2017;12:e0179514.
Fresán U, Rodríguez-Sánchez MA, Reina O, Corces VG, Espinàs ML. Haspin kinase modulates nuclear architecture and Polycomb-dependent gene silencing. PLoS Genet. 2020;16:e1008962.
Maiolica A, de Medina-Redondo M, Schoof EM, et al. Modulation of the chromatin phosphoproteome by the Haspin protein kinase. Mol Cell Proteomics. 2014;13:1724-1740.
Patnaik D, Jun X, Glicksman MA, Cuny GD, Stein RL, Higgins JM. Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. J Biomol Screen. 2008;13:1025-1034.
Huertas D, Soler M, Moreto J, et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene. 2012;31:1408-1418.
Kestav K, Uri A, Lavogina D. Structure, roles and inhibitors of a mitotic protein kinase Haspin. Curr Med Chem. 2017;24:2276-2293.
Eswaran J, Patnaik D, Filippakopoulos P, et al. Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci U S A. 2009;106:20198-20203.
Cuny GD, Ulyanova NP, Patnaik D, et al. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. Bioorg Med Chem Lett. 2012;22:2015-2019.
Tanaka H, Wada M, Park J. HASPIN kinase inhibitor CHR-6494 suppresses intestinal polyp development, cachexia, and hypogonadism in Apcmin/+ mice. Eur J Cancer Prev. 2020;29:481-485.
Nishida-Fukuda H, Tokuhiro K, Ando Y, Matsushita H, Wada M, Tanaka H. Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines. PLoS One. 2021;16:e0249912.
Han L, Wang P, Sun Y, Liu S, Dai J. Anti-melanoma activities of Haspin inhibitor CHR-6494 deployed as a single agent or in a synergistic combination with MEK inhibitor. J Cancer. 2017;8:2933-2943.
Wang P, Hua X, Bryner YH, Liu S, Gitter CB, Dai J. Haspin inhibition delays cell cycle progression through interphase in cancer cells. J Cell Physiol. 2020;235:4508-4519.
Sakaue-Sawano A, Kurokawa H, Morimura T, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 2008;132:487-498.
Massillon D, Stalmans W, van de Werve G, Bollen M. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem J. 1994;299(Pt 1):123-128.
Balzano D, Santaguida S, Musacchio A, Villa F. A general framework for inhibitor resistance in protein kinases. Chem Biol. 2011;18:966-975.
Nelson L, Tighe A, Golder A, et al. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. Nat Commun. 2020;11:822.
Aspinall CF, Zheleva D, Tighe A, Taylor SS. Mitotic entry: non-genetic heterogeneity exposes the requirement for Plk1. Oncotarget. 2015;6:36472-36488.
Fong CS, Mazo G, Das T, et al. 53BP1 and USP28 mediate p53-dependent cell cycle arrest in response to centrosome loss and prolonged mitosis. eLife. 2016;5:e16270.
Lambrus BG, Daggubati V, Uetake Y, et al. A USP28-53BP1-p53-p21 signaling axis arrests growth after centrosome loss or prolonged mitosis. J Cell Biol. 2016;214:143-153.
Uetake Y, Sluder G. Prolonged prometaphase blocks daughter cell proliferation despite normal completion of mitosis. Curr Biol. 2010;20:1666-1671.
Meitinger F, Anzola JV, Kaulich M, et al. 53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration. J Cell Biol. 2016;214:155-166.
Chen JG, Yang CP, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res. 2003;63:7891-7899.
Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle. 2007;6:70-74.
May E, Jenkins JR, May P. Endogenous HeLa p53 proteins are easily detected in HeLa cells transfected with mouse deletion mutant p53 gene. Oncogene. 1991;6:1363-1365.
Huang M, Feng X, Su D, et al. Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition. Oncogene. 2020;39:4312-4322.
Melms JC, Vallabhaneni S, Mills CE, et al. Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic antitumor activity. Cancer Res. 2020;80:798-810.
Zhu D, Gu X, Lin Z, Yu D, Wang J, Li L. HASPIN is involved in the progression of gallbladder carcinoma. Exp Cell Res. 2020;390:111863.

Auteurs

Peiling Wang (P)

School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, P. R. China.
Division of Pharmaceutical Sciences, School of Pharmacy, The University of Wisconsin, Madison, Wisconsin, USA.

Xiangmei Hua (X)

Division of Pharmaceutical Sciences, School of Pharmacy, The University of Wisconsin, Madison, Wisconsin, USA.

Yang Sun (Y)

Division of Pharmaceutical Sciences, School of Pharmacy, The University of Wisconsin, Madison, Wisconsin, USA.

Hongyu Li (H)

Division of Pharmaceutical Sciences, School of Pharmacy, The University of Wisconsin, Madison, Wisconsin, USA.

Yuge Han Bryner (YH)

Division of Pharmaceutical Sciences, School of Pharmacy, The University of Wisconsin, Madison, Wisconsin, USA.

Richard P Hsung (RP)

Division of Pharmaceutical Sciences, School of Pharmacy, The University of Wisconsin, Madison, Wisconsin, USA.

Jun Dai (J)

Division of Pharmaceutical Sciences, School of Pharmacy, The University of Wisconsin, Madison, Wisconsin, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH